PE20191544A1 - Composiciones de arsenico - Google Patents
Composiciones de arsenicoInfo
- Publication number
- PE20191544A1 PE20191544A1 PE2019000939A PE2019000939A PE20191544A1 PE 20191544 A1 PE20191544 A1 PE 20191544A1 PE 2019000939 A PE2019000939 A PE 2019000939A PE 2019000939 A PE2019000939 A PE 2019000939A PE 20191544 A1 PE20191544 A1 PE 20191544A1
- Authority
- PE
- Peru
- Prior art keywords
- tetraoxide
- excipient
- composition
- arsenic
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229910052785 arsenic Inorganic materials 0.000 title 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 title 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
- 150000001342 alkaline earth metals Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002274 desiccant Substances 0.000 abstract 1
- FFCZHQLUEDCQKI-UHFFFAOYSA-N diarsenic Chemical compound [As]#[As] FFCZHQLUEDCQKI-UHFFFAOYSA-N 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000002270 dispersing agent Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Referido a una composicion farmaceutica oral de forma solida que comprende un tetraoxido de diarsenico de formula MHAs2O4 y un excipiente farmaceuticamente aceptable; donde dicho tetraoxido es un metal alcalino y/o un metal alcalinoterreo y el excipiente es seleccionado de uno o mas de un agente de secado; un desintegrante y un dispersante. Dicha composicion es util para el tratamiento de cancer como leucemia promielocitica aguda y mieloma multiple.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016904945A AU2016904945A0 (en) | 2016-12-01 | Arsenic compositions | |
| PCT/AU2017/050807 WO2018098519A1 (en) | 2016-12-01 | 2017-08-02 | Arsenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191544A1 true PE20191544A1 (es) | 2019-10-24 |
Family
ID=62240940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000939A PE20191544A1 (es) | 2016-12-01 | 2017-08-02 | Composiciones de arsenico |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11241453B2 (es) |
| EP (1) | EP3548044B1 (es) |
| JP (2) | JP7080230B2 (es) |
| KR (1) | KR102487884B1 (es) |
| CN (1) | CN109952105A (es) |
| AU (1) | AU2017368444B9 (es) |
| CA (1) | CA3041357A1 (es) |
| CL (1) | CL2019001422A1 (es) |
| DK (1) | DK3548044T3 (es) |
| ES (1) | ES2964979T3 (es) |
| IL (1) | IL265986B (es) |
| MX (1) | MX384297B (es) |
| NZ (1) | NZ752214A (es) |
| PE (1) | PE20191544A1 (es) |
| PL (1) | PL3548044T3 (es) |
| SA (1) | SA519401885B1 (es) |
| SG (1) | SG11201903064SA (es) |
| TW (1) | TWI808060B (es) |
| WO (1) | WO2018098519A1 (es) |
| ZA (1) | ZA201902156B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017305945B2 (en) | 2016-08-01 | 2019-11-21 | Veolia Water Solutions & Technologies Support | Process for removing silica from produced water and other wastewater streams |
| TWI808060B (zh) * | 2016-12-01 | 2023-07-11 | 澳大利亞商益友製藥私人有限公司 | 砷組成物 |
| CA3211092A1 (en) * | 2021-02-26 | 2022-09-01 | Intas Pharmaceuticals Ltd. | Oral pharmaceutical composition of arsenic trioxide |
| JP2022151442A (ja) * | 2021-03-26 | 2022-10-07 | 均 石井 | 白血病治療薬。 |
| EP4455672A1 (en) | 2023-04-26 | 2024-10-30 | Medsenic | Method and kit for diagnosing and monitoring chronic graft-versus-host disease (cgvhd) using particular cytokine biomarkers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2080004A (en) * | 1933-05-17 | 1937-05-11 | Frederick E Dearborn | Double salt of copper arsenite and a copper salt of an unsaturated fatty acid and process of making the same |
| US3280046A (en) | 1963-03-27 | 1966-10-18 | Dow Chemical Co | Polyol ether resins and utility |
| ES2358624T3 (es) | 1997-10-15 | 2011-05-12 | Polarx Biopharmaceuticals, Inc. | Composiciones y métodos para el tratamiento de enfermedades neoplásicas primarias y metastásicas usando compuestos de arsénico. |
| EP2255800B1 (en) | 1997-11-10 | 2012-10-17 | Memorial Sloan Kettering Cancer Center | Arsenic trioxide for use in the treatment of leukaemia |
| CN1471925A (zh) | 2002-08-02 | 2004-02-04 | 丛繁滋 | 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法 |
| US7521071B2 (en) | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| CN102060722B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种含砷化合物及其制备方法和用途 |
| EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| CN105435228B (zh) * | 2014-08-14 | 2020-08-07 | 中国科学院上海营养与健康研究所 | 三氧化二砷的抗肿瘤新用途及抗肿瘤制剂 |
| PL3250213T3 (pl) * | 2015-01-29 | 2023-10-30 | Eupharma Pty Ltd | Kompozycje zawierające arsen do stosowania w sposobach leczenia |
| TWI790191B (zh) * | 2015-02-01 | 2023-01-21 | 美商錫羅斯製藥公司 | 用於病患口服之含砷高表面積冷凍乾燥組合物 |
| TWI808060B (zh) | 2016-12-01 | 2023-07-11 | 澳大利亞商益友製藥私人有限公司 | 砷組成物 |
-
2017
- 2017-08-02 TW TW106126050A patent/TWI808060B/zh active
- 2017-08-02 KR KR1020197013881A patent/KR102487884B1/ko active Active
- 2017-08-02 IL IL265986A patent/IL265986B/en unknown
- 2017-08-02 PE PE2019000939A patent/PE20191544A1/es unknown
- 2017-08-02 WO PCT/AU2017/050807 patent/WO2018098519A1/en not_active Ceased
- 2017-08-02 MX MX2019006107A patent/MX384297B/es unknown
- 2017-08-02 CA CA3041357A patent/CA3041357A1/en active Pending
- 2017-08-02 SG SG11201903064SA patent/SG11201903064SA/en unknown
- 2017-08-02 EP EP17876251.4A patent/EP3548044B1/en active Active
- 2017-08-02 NZ NZ752214A patent/NZ752214A/en unknown
- 2017-08-02 CN CN201780069613.2A patent/CN109952105A/zh active Pending
- 2017-08-02 US US16/465,693 patent/US11241453B2/en active Active
- 2017-08-02 DK DK17876251.4T patent/DK3548044T3/da active
- 2017-08-02 ES ES17876251T patent/ES2964979T3/es active Active
- 2017-08-02 JP JP2019524985A patent/JP7080230B2/ja active Active
- 2017-08-02 AU AU2017368444A patent/AU2017368444B9/en active Active
- 2017-08-02 PL PL17876251.4T patent/PL3548044T3/pl unknown
-
2019
- 2019-04-05 ZA ZA2019/02156A patent/ZA201902156B/en unknown
- 2019-05-27 CL CL2019001422A patent/CL2019001422A1/es unknown
- 2019-05-29 SA SA519401885A patent/SA519401885B1/ar unknown
-
2022
- 2022-02-25 JP JP2022028046A patent/JP7419415B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3548044A1 (en) | 2019-10-09 |
| CL2019001422A1 (es) | 2019-08-02 |
| NZ752214A (en) | 2022-11-25 |
| KR102487884B1 (ko) | 2023-01-11 |
| AU2017368444A1 (en) | 2019-04-18 |
| TW201821087A (zh) | 2018-06-16 |
| JP7419415B2 (ja) | 2024-01-22 |
| SA519401885B1 (ar) | 2023-12-24 |
| AU2017368444B9 (en) | 2020-07-02 |
| MX2019006107A (es) | 2019-08-21 |
| KR20190089865A (ko) | 2019-07-31 |
| JP2022069485A (ja) | 2022-05-11 |
| ZA201902156B (en) | 2021-01-27 |
| SG11201903064SA (en) | 2019-05-30 |
| TWI808060B (zh) | 2023-07-11 |
| JP2020500845A (ja) | 2020-01-16 |
| EP3548044A4 (en) | 2020-07-22 |
| PL3548044T3 (pl) | 2024-03-04 |
| US11241453B2 (en) | 2022-02-08 |
| BR112019007498A2 (pt) | 2019-07-02 |
| IL265986A (en) | 2019-06-30 |
| AU2017368444B2 (en) | 2020-04-30 |
| US20200016196A1 (en) | 2020-01-16 |
| CA3041357A1 (en) | 2018-06-07 |
| EP3548044B1 (en) | 2023-09-20 |
| JP7080230B2 (ja) | 2022-06-03 |
| DK3548044T3 (en) | 2023-12-11 |
| CN109952105A (zh) | 2019-06-28 |
| MX384297B (es) | 2025-03-14 |
| WO2018098519A1 (en) | 2018-06-07 |
| ES2964979T3 (es) | 2024-04-10 |
| IL265986B (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191544A1 (es) | Composiciones de arsenico | |
| BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
| CL2017001650A1 (es) | Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis. | |
| MY210123A (en) | Tlr7/8 antagonists and uses thereof | |
| PE20171238A1 (es) | Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos | |
| UY35975A (es) | Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| PH12017502051A1 (en) | TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | |
| MX2017004600A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| PE20171646A1 (es) | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia | |
| EA201891586A1 (ru) | Антипролиферативные соединения и их фармацевтические композиции и применения | |
| MX2016013431A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| ES2721649T3 (es) | Comprimidos de N-acetilcisteína tragables | |
| CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| DOP2016000268A (es) | Compuestos de azol amidosustituidos como inhibidores de tnks1 y/o tnks2 | |
| MX2019012665A (es) | Compuestos organicos. | |
| MX2017007955A (es) | Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas. | |
| ECSP18038014A (es) | Bloqueador del canal de sodio | |
| EP4352194C0 (en) | COMPOSITION OF TABLET | |
| CL2019002025A1 (es) | Derivados de pirrolotriazina como inhibidor de cinasas. | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| MA39877A (fr) | Formes solides d'un composé pharmaceutiquement actif | |
| UY37444A (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso | |
| CR20170125A (es) | Composición farmacéutica sólica que comprende amlodipina y losartán |